Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal, Arun J et al.·Nature medicine·2024·
RPEP-092062024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Published In:
Nature medicine, 30(7), 2037-2048 (2024)
Database ID:
RPEP-09206

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-09206·https://rethinkpeptides.com/research/RPEP-09206

APA

Sanyal, Arun J; Kaplan, Lee M; Frias, Juan P; Brouwers, Bram; Wu, Qiwei; Thomas, Melissa K; Harris, Charles; Schloot, Nanette C; Du, Yu; Mather, Kieren J; Haupt, Axel; Hartman, Mark L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine, 30(7), 2037-2048. https://doi.org/10.1038/s41591-024-03018-2

MLA

Sanyal, Arun J, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.." Nature medicine, 2024. https://doi.org/10.1038/s41591-024-03018-2

RethinkPeptides

RethinkPeptides Research Database. "Triple hormone receptor agonist retatrutide for metabolic dy..." RPEP-09206. Retrieved from https://rethinkpeptides.com/research/sanyal-2024-triple-hormone-receptor-agonist

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.